How to Find Clinical Experts for a Medtech Startup

You are building a medtech product and you have hit the point where founder intuition is no longer enough. You need working clinicians who can tell you whether your workflow is real, whether your evidence plan will convince a commissioner, and whether the label you drafted is honest. This post is the practical guide to how to find clinical experts for a medtech startup in the UK, without wasting three months on LinkedIn cold outreach that goes nowhere.

Why sourcing clinical experts is the bottleneck, not a nice-to-have

Every pre-market medtech eventually hits the same wall. The engineering is progressing, the pitch deck exists, and then a customer, an investor, or the MHRA guidance on software as a medical device asks a clinical question the founding team cannot answer with authority. At that moment you need a named clinician, in the relevant specialty, with time on their calendar this week.

Founders often treat clinical input as a phase-two problem. That is the mistake. If you leave sourcing clinical experts until after your first prototype, you will rebuild the prototype.

Every serious medtech investor already knows this, which is why "who is your clinical lead" appears in the first ten questions of most healthcare VC diligence calls. Treating clinical sourcing as a commercial workstream from day one is what separates the teams that raise a Series A from the teams that stall at seed.

Where founders actually find useful clinicians

Here is the opinion most agencies will not tell you: LinkedIn is the worst first channel and the best fourth channel. Cold-messaging consultants on LinkedIn has a reply rate close to zero, and the ones who do reply are often the least in-demand. You will burn six weeks and end up with an advisor whose main qualification is that they were bored on a Tuesday.

The channels that actually work, in the order you should try them:

1. Warm intros through condition-specific charities and patient groups. The clinical leads of Diabetes UK, Cancer Research UK, Stroke Association, and the equivalents in your specialty already know which clinicians are receptive to industry partnership and which are not.
2. Royal college special interest groups. The RCP, RCS, RCGP, RCPsych, and their specialty associations run committees on digital health, AI, and innovation. The chairs of those committees are, by definition, senior clinicians who have chosen to spend time on medtech topics.
3. NIHR Applied Research Collaborations and NHS innovation hubs. ARCs, Health Innovation Networks (formerly AHSNs), and academic health science centres are set up to broker exactly this kind of introduction.
4. Curated marketplaces for clinical experts. Platforms like Orbion Connect exist specifically to match healthtech companies with vetted UK clinicians who have opted in to paid advisory work, with GMC, NMC, or HCPC status already checked. Case studies from other founders who have used the same channel sit on our case studies page.
5. LinkedIn, as a follow-up channel. Once you have a shortlist from the first four, LinkedIn is useful for the second-degree connection request and for reading recent posts. It is not useful as a first-touch tool.

The founders who move fastest treat sourcing as a portfolio problem. You want three or four clinicians across primary care, secondary care, and, if relevant, allied health or nursing, rather than one consultant who becomes a bottleneck.

What to pay, and how to structure the engagement

Founders consistently underpay for clinical time, then wonder why advisors ghost them. The current UK market for medtech clinical advisory work sits in the following bands, based on what our platform sees each month:

• Ad hoc consulting call, single hour: £150 to £400, depending on seniority and specialty scarcity.
• Retainer for a clinical advisor, four to six hours per month: £1,000 to £3,000 per month, or the equity equivalent.
• Clinical safety officer (DCB0129 and DCB0160) engagement: £5,000 to £15,000 for the initial safety case, plus a monthly retainer.
• Named clinical lead on a formal advisory board: typically 0.25% to 0.75% equity vesting over two to three years, plus meeting fees.

Equity-only arrangements can work at pre-seed but they usually do not scale. A consultant respiratory physician who is already turning down three offers a month will not take equity in your prototype without a cash component. The correct model at seed and beyond is a small cash retainer plus a modest equity slice, structured so both sides can exit cleanly at twelve months.

Watch the GMC, NMC, and HCPC declarations. UK clinicians in active practice have a duty to disclose commercial interests, and if you push them to sign anything that conflicts with that duty, you have created a compliance problem for them and a reputation problem for you.

How to vet a clinical expert for medtech work

Clinical seniority does not equal medtech usefulness. A brilliant surgeon can be a poor advisor if they have never been through a regulatory submission, and a mid-career specialty registrar with two years at a digital health startup will often out-perform a knighted professor.

Vet on four axes:

• Regulatory literacy. Have they read the MHRA guidance on their device class? Have they worked on a technical file, a clinical evaluation report, or a post-market surveillance plan?
• Workflow realism. Can they walk you through the exact clinical pathway your product touches, including the boring bits like coding, referral thresholds, and who gets sued if something goes wrong?
• NHS commercial fluency. Do they know what an ICB is, how the NHS procurement frameworks work in 2026, and what "in tariff" means for their specialty?
• Time honesty. Will they actually be available in the weeks when you need them, or are they a professor with a full clinic list and three grant deadlines?

A twenty-minute vetting call, structured around those four axes, will save you from six months of pretend advisory relationships.

Three examples: a startup that got it right, an NHS example, and a failure

Startup example. A London-based cardiology AI startup we work with needed a clinical lead for their MHRA submission. They spent three weeks going through a specialty association, shortlisted four consultant cardiologists, ran paid two-hour scoping calls with each, and appointed one on a £2,500 monthly retainer plus 0.5% equity. Their clinical evaluation report passed first-round review at their notified body without material queries. Total time from first outreach to signed engagement: 34 days.

NHS example. The NHS AI Lab's AI Airlock regulatory sandbox has been quietly matching digital health companies with NHS clinical assessors for sandbox work. Founders often overlook it because it is not marketed as a matching service, but the clinicians who assess in the Airlock are precisely the profile you want on your advisory board. If you have an active regulatory query, applying to a sandbox is one of the cheapest ways to get senior clinical scrutiny.

Failure example. A digital mental health company (Series A, US-founded, expanding into the UK) hired a well-known professor of psychiatry as their UK clinical advisor on a £4,000 monthly retainer, cash only, on a handshake. Twelve months later the professor had attended two meetings, never reviewed the clinical safety case, and had listed the company on their conflicts declaration in a way that blocked their own NHS trust from procuring the product. The company paid £48,000 for negative value. The failure was structural, not personal: no scope of work, no deliverables, no exit clause, and no check on whether the advisor's day job would create a procurement conflict.

A shortlist of practical next steps

If you take one thing from this post, do these five things this week:

1. Write down the three specific clinical questions you cannot currently answer. That is your advisor brief.
2. Identify the two royal college special interest groups closest to your product and email the chair.
3. Post a scoped, paid advisory role (not a "hey, would love to chat") on a curated clinical marketplace.
4. Draft a one-page scope of work with monthly deliverables, a cash retainer, and a twelve-month review clause.
5. Book a call with your regulatory consultant before you sign the advisor, so the clinician's remit lines up with your technical file rather than against it.

Clinical experts are the single highest-leverage hire a medtech founder makes in year one. Treat sourcing them as a serious commercial process, pay them properly, scope the work tightly, and you will move faster than 80% of your competitors on the same regulatory pathway.